PGR and breast cancer: To evaluate whether this data-driven cutoff may be generalisable to other cohorts and thus a feasible clinical strategy, we assessed the distribution of ESR1 and PGR expression in an independent cohort of metastatic breast cancer that includes GEX data from primary tumours and distant metastases.